Business Context and Reporting Period
This Form 8-K was filed by Catalyst Biosciences, Inc. (CBIO) on February 7, 2020. The report details significant clinical developments and a commercial collaboration update presented at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The only specific financial metric disclosed is a $15 million upfront payment received from Biogen International GmbH in January 2020 under a collaboration agreement for CB 2782-PEG. The filing notes that Mosaic Biosciences, Inc. is entitled to a double-digit percentage of these funds.
Material Changes and Clinical Developments
- DalcA (Hemophilia B): Phase 2b trial data showed that 28 days of daily subcutaneous (SQ) dosing achieved protective Factor IX (FIX) levels >12%. Steady state levels reached up to 27% after 14 days with no bleeds. No serious adverse events or anti-drug antibodies were reported. Three subjects experienced mild injection site reactions.
- MarzAA (Hemophilia A/B): Phase 1 data indicated SQ dosing reaches target levels for treating ongoing bleeding. Preclinical data in mice showed on-demand treatment was as efficient as intravenous NovoSeven in reducing bleeding.
- Gene Therapy: Preclinical data suggested a novel chimeric AAV capsid combined with CB 2679d-GT FIX may reduce vector dose requirements while maintaining high FIX levels.
Outlook, Risks, and Management Commentary
Management highlighted the potential for DalcA to change the treatment paradigm for hemophilia B through effective prophylaxis with SQ dosing. The filing includes standard forward-looking statements regarding the potential benefits of DalcA, MarzAA, and gene therapy assets.
Risks and Contingencies: The company warns that actual results may differ due to trial delays, unsatisfactory outcomes, failure of human trials to replicate earlier results, potential adverse effects (including antibody generation), and higher-than-anticipated development costs.
Investor Verification Checklist
- Verify the exact amount of the $15 million Biogen payment received in January 2020 and the specific percentage share owed to Mosaic Biosciences.
- Confirm the timeline for the next phase of DalcA clinical trials following the Phase 2b results.
- Review the "Risk Factors" section of the November 7, 2019 quarterly report for detailed risks regarding antibody generation and manufacturing costs.
- Monitor for updates on the Phase 1 MarzAA study to confirm if human data supports the preclinical mouse model results.